Overview

A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal